Introduction
Myocardial infarction (MI) is the leading cause of mortality and morbidity worldwide. 1 Typically MI is caused by plaque rupture, leading to exposure of thrombogenic material and formation of vesseloccluding thrombi. Consequent oxygen and nutrient deprivation and build-up of metabolic waste products quickly lead to myocardial damage and tissue death if circulation is not restored promptly. While early restoration of circulation is desirable, reperfusion is now recognized as a contributor to localized inflammatory response, resulting in substantial cardiac tissue damage. 2 Tissue or cellular damage releases extracellular nucleotides (ATP and ADP), which trigger inflammation, platelet-mediated thrombosis, and further cell death. These extracellular nucleotides are mainly hydrolysed by two enzymes, the ectonucleoside triphosphate diphosphohydrolase-1 (ENTPD1) CD39 and the ecto-5-nucleotidase CD73 thereby altering an ATP/ADP-driven pro-inflammatory milieu to an adenosine-induced anti-inflammatory environment. 3, 4 As such, CD39 appears to be an attractive therapeutic drug candidate with anti-inflammatory and anti-thrombotic effects. However, systemic administration of CD39 can have the detrimental side effect of bleeding complications. 5 To prevent this, we have previously shown that CD39 can be genetically fused to create a targeted therapeutic construct, which can be administered at low enough concentrations to avoid bleeding side effects, while enriching itself in the targeted area. 5 Platelets are known to accumulate in reperfused myocardial tissue, with their numbers strongly correlating to the size of ischaemic and necrotic areas. 6 We have recently provided further evidence of platelet accumulation/aggregation after cardiac ischaemia via molecular PET imaging using an activated platelet-targeted radiotracer, via flow cytometry and immunostaining. 7 As such, we hypothesised that activated platelets present an ideal target to enrich CD39 to the ischaemic myocardium.
We employed a single-chain (scFv) antibody directed against the activated form of glycoprotein (GP)IIb/IIIa (a IIb /b IIIa ; CD41/CD61) genetically fused to the extracellular domain of human CD39. This unique scFv antibody ensures that CD39 enriches on activated platelets only, rather than binding to circulating platelets. Specificity, sensitivity and suitability of this scFv as a targeting tool have been previously demonstrated, 8 as well as specific accumulation in ischaemic myocardium after ischaemia/reperfusion (I/R). 6, 7 Here, we show the benefits of activated platelet-targeted CD39 therapy in a reperfusion model of MI.
Methods
Briefly, C57Bl/6J mice underwent I/R injury by left anterior descending (LAD) coronary artery ligation, as described previously. 9 Mice were treated with either Targ-CD39, Non-targ-CD39, or phosphate buffered saline (PBS). Possible side effects such as bleeding, blood gases as well as heart and respiration rate (2 h post-MI), cytokine profiling (3 days post-MI), weekly echocardiography and histological analysis (2 h and 4 weeks post-MI) were assessed. Further information can be found in the Supplementary material online, Methods.
Results and discussion
CD39 has previously been implicated to play an important role in several pathophysiological conditions such as cancer, 10 autoimmune diseases, 3 and I/R injury 11 and was recently shown to ameliorate MI in mouse models with heart tissue-specific overexpression. 12 Increasing CD39 levels in vivo, via either administration or genetic overexpression, however, has been shown to result in an increased bleeding tendency. 4 While this effect is concentration-dependent, 5 a bleeding tendency persists at the concentration of CD39 that is required to prevent thrombus formation. 5 Our group has previously established a strategy to specifically target CD39 to activated platelets to prevent thrombus formation without causing haemostatic problems. 5 Whether the low systemic concentration of targeted-CD39 (Targ-CD39) has potential to harness the benefits of CD39 at the site of a complex ischaemic event such as MI, but at the same time avoiding bleeding complications was assessed using a mouse model of myocardial I/R. Mice were treated with Targ-CD39, Non-targ-CD39 (a mutated, non-binding version of Targ-CD39) or PBS (see Supplementary material online, Figures S1 and S2). Treatment with Targ-CD39 resulted in continuous improvement of echocardiographically determined ejection fraction (EF, Figure 1A and B, Supplementary material online, Video S1) and fractional shortening (FS, Supplementary material online, Figure S3 ) 1, 2, 3, and 4 weeks post-I/R. A significant increase in EF and FS was observed at week 3 and 4 for the Targ-CD39 mice, compared with PBS and Non-targ-CD39 mice.
At week 4 post-I/R, echocardiography showed a significant decrease in left ventricular (LV) wall measurements and in cardiac output for PBS and Non-targ-CD39 treated groups but not in the Targ-CD39 treated group (Supplementary material online, Figures S4  and S5) .
In our study, we chose to use the Simpson calculation for more precise LV function measurements. Additionally, we performed strain analysis, a clinically well-established method for the detection of myocardial dysfunction. Strain analysis reflects myocardial contractility more accurately than conventional echocardiography and is a better clinical predictor of mortality as compared to EF and the wall motion score index. 13, 14 We observed that pathological changes in strain were prevented by treatment with Targ-CD39, compared with Non-targ-CD39 and PBS treated mice. This result is consistent with a clinical study observing less myocardial damage and deformation in patients who had early reperfusion, as compared to those with delayed reperfusion. 13 Radial and longitudinal strain analysis indicated that this cardiac performance was retained 4 weeks post-I/R for the Targ-CD39 treated animals, but reduced for PBS and Non-targ-CD39 treated animals ( Figure 1C and D, Supplementary material online, Figure S6 ).
To assess possible side effects of treatment with Targ-CD39, we performed tail transection in mice after I/R injury. Bleeding times proved not to be different between Non-targ-CD39, Targ-CD39, and PBS treated mice ( Figure 1E) . Also, blood gases, respiration, and heart rate did not reveal treatment differences (Supplementary material online, Figures S7 and S8) . However, the study size might be too small to definitely exclude side effects of Targ-CD39 treatment.
Serological cardiac biomarkers such as cardiac troponins or hearttype fatty acid binding protein (H-FABP) were used to diagnose MI. All mice showed elevated cardiac troponin I (cTnI) levels (Supplementary material online, Figure S9 ). However, H-FABP, which has been shown to be a more heart-specific, early-released, accurate biomarker for early estimation of infarct size, 15 showed a significantly attenuated increase in plasma H-FABP 2 h post-I/R in Targ-CD39 treated mice compared with PBS and Non-targ-CD39 treated animals ( Figure 2A) . These assessments were supported by histological evaluation of infarct size 4 weeks post-I/R. Targ-CD39 treated mice showed a significant decrease in infarct size (I)/area at risk (AaR) ratio, compared with PBS and Non-targ-CD39 treated animals ( Figure 2B ). This reduced infarct size was accompanied by increased capillary density in the infarct zone of the Targ-CD39 treated mice at week 4, compared with both control groups ( Figure 2C) . A promoting role of CD39 in angiogenesis has previously been proposed. 16 Goepfert et al. demonstrated disordered cellular infiltration and angiogenesis in A possible additional effect of CD39 is its attenuation of microthrombi formation. Therefore, we measured CD41 mRNA expression and performed immunostaining of platelets in the ischaemic myocardium. Two hours post-I/R injury, Targ-CD39 treatment significantly decreased the expression of CD41 mRNA within the ischaemic myocardium compared with mice treated with Non-targ-CD39 ( Figure 2D ). Furthermore, a significant reduction in platelet surface coverage in Targ-CD39 treated mice compared with Non-targ-CD39 treated mice was detected using histological staining of platelets ( Figure 2E ). Platelets are known to be contributors to the noflow phenomenon after reperfusion of a blocked coronary artery. One of the mechanisms postulated is intraluminal platelet microthrombi. 17, 18 As we have previously shown that Targ-CD39 prevents thrombus formation and vessel occlusion, we postulated that this same mechanism would be able to prevent thrombi from forming in small cardiac vessels and capillaries after reperfusion, thereby preventing further ischaemic tissue damage. Since both ultrasound analysis and histological data indicated marked improvement of infarct size and preservation of cardiac function for the Targ-CD39 treated mice compared with the control groups, we investigated cytokine responses in the myocardium for Targ-CD39 and Non-targ-CD39 treated mice. At day 3 post-I/R, a profiler array showed that 32 inflammatory cytokines and receptors were down-regulated more than twofold in the Targ-CD39 treatment group, compared with the control group ( Figure 2F , Supplementary material online, Table S1 ). No marker was upregulated. These data demonstrate down-regulation of multiple proinflammatory chemokines and cytokines, many of which are linked to T cells. 19 This indicates that Targ-CD39 leads to a major modification in T cell migration and differentiation and ultimately to less inflammation in the myocardium. To summarize, we showed that Targ-CD39 first reduces the infiltration of platelets and thus microthrombi formation, followed by a change in cytokines and chemokines, which ultimately promotes angiogenesis, preserves LV function and reduces infarct size (Take home figure) . Overall, targeting CD39 to activated platelets holds strong promise for effective protection from I/R injury of the heart and potentially other organs as well. The targeting strategy toward activated GPIIb/ IIIa allows the use of doses that result in concentrations below haemostatic impairment and thus harnesses the potential of strong antiinflammatory and anti-platelet effects without risking bleeding complications. 
